Keyword: Denali Therapeutics
The agreement tasks AbCellera with generating panels of antibodies for up to eight targets picked by Denali.
The partners will work to develop adeno-associated virus vectors capable of crossing the blood-brain barrier.
Sanofi laid out $125 million to take a stake in two of Denali's RIPK1 inhibitors, and now one will be tested in three tough-to-treat brain disorders.
Jnana’s Joanne Kotz to be CEO; BioCardia brings on new clinical VP for phase 3; and Biomatics recruits biopharma veterans for $300M healthcare fund.
Eli Lilly is dropping a BACE inhibitor that was being tested in combination in Alzheimer's disease.
The agreement covers small molecules designed to treat multiple neurodegenerative and systemic inflammatory diseases.
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.
A team of scientists clarified the role of the protein LRRK2 in tuberculosis, suspecting that it behaves similarly in Parkinson's.
Researchers at Washington University School of Medicine have found that targeting the APOE protein helps clear Alzheimer's plaques in mice.
2017 was "good, but not great" for biotech IPOs, yet insider buying was still high at 34%.